Comorbidities in Transsexual Patients under Hormonal Treatment Compared to Age- And Gender-Matched Primary Care Comparison Groups

María Ángeles

Abstract

Background: There is limited data on safety aspects of hormonal treatment in transsexual patients and clinical trials are lacking. We aimed at evaluating the long-term hormonal treatment in transsexual patients. Patients: 95 transsexuals (37 female-to-male (FMT) and 58 male-to-female transsexuals (MFT)) treated between 1996 and 2007 were compared to an age- and gender-matched primary care patient group from the DETECT-cohort (matching 1:3). Results: Compared to age-matched control groups, we did not observe a higher prevalence of lifetime cardiovascular, endocrine or tumoural comorbidities. FMT showed a lower prevalence of endocrine diseases (FMT to females, p=0.008 and FMT to males, p=0.033). MFT showed a lower prevalence of cardiovascular diseases (MFT to females, p=0.005 and MFT to males, p<0.001) and endocrine diseases (MFT to females p<0.001 and MFT to males, p<0.001). Conclusion: There is no indication of an increased risk associated with HT in transsexual patients in Germany\r\n